← Today’s ReceiptsOfficial public filing linked
Public-record receiptR-NJOfficial filing linked
Thomas Kean disclosed SELL $JNJ
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$15K – $50K
Filed
2026-02-19
Trade date
2026-01-23
Disclosure lag
27 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 27 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $15K – $50K, which is the public reporting band rather than an exact profit or loss figure.
42 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Thomas Kean, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 35 lobbying filings and 5 federal contract records.
Source
Official filing ↗
Source: official House/Senate financial disclosure record · filing ID 20034025 · filed 2026-02-19 · disclosed 27d after transaction
Market context
Johnson & Johnson
Sector: Healthcare
Vs SPY: -0.5%
Factual flags
- 35 lobbying filings linked to this ticker.
- 5 federal contract records linked to this ticker.
- 2 nearby same-ticker disclosures in the surrounding 30-day window.
- Traded JNJ 3d after lobbying filing by JOHNSON & JOHNSON SERVICES INC ($1,510,000) (committee overlap: Technology)
- 7 trades filed on 2026-02-19 (batch dump)
- Traded JNJ 4d before federal contract with Department of Veterans Affairs ($44,779)
Member trail
Thomas Kean
U.S. House · NJ-7
House Committee on Energy and CommerceHouse Committee on Foreign Affairs
Ticker trail
$JNJ
Johnson & Johnson
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.